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1Introduction
Coronary artery disease (CAD) is one of the commonest causes of death
in developing and developed world. Metabolic syndrome has become a
major public health problem. Globally the prevalence of metabolic
syndrome is increasing. The metabolic syndrome is a group of risk
factors for cardiovascular disease and diabetes mellitus. It includes
abdominal obesity, dyslipidemia, raised blood pressure, insulin
resistance, and an inflammatory state. Metabolic syndrome is present in
nearly one quarter of all adults and in 40% of adults over 60 years of
age. It is now recognised as a secondary target for intervention in the
National Cholesterol Education Program (NCEP) Adult Treatment Panel
(ATP) III recommendation. Most studies show that 4–10% of patients
with acute myocardial infarction (AMI) are below 45 years of age. There
are limited data on the risks associated with the metabolic syndrome in
the increasingly large group of young patients who have sustained an
AMI. The aim of this study, therefore, is to assess the prevalence of the
metabolic syndrome in young patients with AMI, by using the IDF
definitions.
2AIM OF THE STUDY
1. To study the prevalence of metabolic syndrome in young patients
with acute myocardial infarction.
2. To find the prevalence of individual components of metabolic
syndrome in the study population.
3REVIEW OF LITERATURE
The metabolic syndrome also called as syndrome X is a collection of
metabolic abnormalities that confer a person with it to high danger of
cardiovascular disease and diabetes.
PREVALENCE OF THE METABOLIC SYNDROME
The metabolic syndrome is increasing in prevalence as result of rapid
urbanisation. In Sub-Saharan Africa, a study done by International
Diabetes Federation to diagnose metabolic syndrome, found the low
prevalence of metabolic syndrome in rural population compared with a
higher prevalence in urban population. Equally, using ATP III definition
of metabolic syndrome, there was significant absence of the metabolic
syndrome in rural men and rural women, and very low prevalence of MS
in urban men (0.5%) and in urban women (0.2%). Higher rates were
found when the WHO criteria are used, being 1.8% (rural) and (5.9%)
urban women and 1.9% (rural) 7.3 % (urban) men.
With any of both the criteria’s i.e. WHO and IDF, urban rates were
higher, both in women and men compared to rural rates. The reason for
the lower occurrence of metabolic syndrome in rural areas was the high
level of physical activity in Saharan African countries.
4Analysing the prevalence of individual risk factors in Sub-Saharan
Africa revealed that, the elevated serum triglyceride was the least
frequent for both women (0.3%) and men (1.4 %). The most common
abnormality was hypertension.
In a study done among Zimbabwe in type 2 diabetic patients, to
determine the prevalence of Metabolic syndrome revealed that 43% of
the patients had metabolic syndrome.
Metabolic syndrome was also seen in 25.2% of type 2 diabetic patients
in Nigeria. However the systemic hypertension was found to be the
commonest component of metabolic syndrome by 38.5%. This study
concluded that metabolic syndrome is associated with very high risk of
stroke, peripheral vascular disease and microalbuminuria and kidney
disease.
In a study conducted in Eastern India by D.S. Prasad et al, the
prevalence rates of MS were 33.5% of which  24.9 % were  males and
42.3% were females.
In another study conducted by Gupta R et al, MS was present in 31.6%
subjects overall ; among which men contributed 22.9% and women
about 39.9%.
5THE RISK FACTORS FOR METABOLIC SYNDROME
I. Overweight and Obesity
Obesity is an important risk factor for both metabolic syndrome and
coronary artery disease. Majority of patients with CAD are obese.
Severity of CAD is higher among obese individuals when compared to
non obese individuals. Obesity is a cumulative risk factor for diabetes,
CAD, hypertension and lipid abnormalities.
II. Physical inactivity
Physical inactivity is one of paramount risk factors for the development
of metabolic syndrome. Physical inactivity is an essential contributing
factor for obesity, hypertension, and hyper-lipidaemia. Physical activity
is an important interventional component, in terms of treatment and
prevention of MS.
III. Aging and sex
As the age increases, the prevalence of metabolic syndrome also
increases. Metabolic syndrome is present in nearly half of the US
population over the age of 50years. After 60years the incidence is more
in women than men.
6IV. Glucose intolerance
A large proportion of men with type 2 diabetes will have MS. Hypo-
adiponectinemia increases insulin resistance and is an important risk
factor for development of metabolic syndrome.
V. Dyslipidemia
Dyslipidemia comprises of greatly elevated level triglyceride levels ,
lower concentration of HDL cholesterol and higher levels of small and
dense LDL. This abnormality of lipids leads to a insulin resistance,
which predisposes a person to develop CVD. Lower HDL-C and higher
levels of triglycerides are the constituents which are included in the
various definitions of metabolic syndrome.
VI. Lipodystrophy
Lipodystrophic disorders are associated with the metabolic syndrome.
Both genetic syndromes  (e.g., Berardinelli-Seip congenital
lipodystrophy & Dunnigan familial partial lipodystrophy) and acquired
causes (e.g., HIV-related lipodystrophy in patients treated withHAART)
forms of lipodystrophy can lead  to severe insulin resistance and
metabolic syndrome.
7VII. Smoking
Smoking is a significant risk factor for the progression of coronary heart
disease (CHD). Smoking incites insulin resistance. Insulin resistance is
the underlying metabolic abnormality for the development of metabolic
syndrome.
Smoking leads to increase in the levels of hormones which counter the
effects of insulin. GH, adrenaline is some mediators of this action.
The process of how cigarette smoking causes MS is not yet clear.
Fat oxidation controls the body adipose stores. Smoking increases the
oxidation of FFA. So, upon smoking cessation the rate of fatty acid
oxidation decreases which may lead to weight gain and development of
MS. This can be prevented by decreasing the caloric consumption.
Constituents of Metabolic Syndrome
The constituents of syndrome X are:
 Visceral adiposity
 Dyslipidemia
 Systemic hypertension
 Insulin resistance
 Increased waist circumference
Each component is defined as follows:
8 Visceral adiposity: visceral adiposity is a powerful risk factor for
the development of metabolic syndrome.
BMI (body mass index) is defined as weight in kilogram divided
by height in metre square. BMI is an important parameter to
measure of obesity.
Classification of overweight and obesity by BMI
the main disadvantage of BMI is it does not convey information
about the distribution of body fat.  South Asians have higher levels
of abdominal fat in viscera and a greater degree of insulin
resistance at comparably lower levels of BMI, which reveals that
BMI alone cannot be relied upon t estimate the correct risk in
Indian population. Now the obesity cut off for Indian population is
reduced from BMI >30 to BMI >25.
9CLASSIFICATION OF OBESITY
Android obesity: it is the collection of adipose tissue in the
abdomen above the waist. It is also called central obesity or apple
type obesity and is linked to high prevalence of CAD, DM, and
hypertension.
Gynoid obesity : it is the collection of adipose tissue in the hips
and buttocks,  that is, below the waist. It is also called as pear
shaped obesity. This type of obesity confers less risk of DM, HT
but more to mechanical disorders like varicose veins and arthritis.
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Measurement of central obesity
Waist hip ratio
Most common measure of central obesity is waist hip ratio. Since
the excess fat is distributed in the hp in women and waist in men,
the optimum value for waist hip ratio is lower in women than in
men. In Indians the mean waist hip ratio is 0.93 in men and 0.84 in
women.
Waist hip ratio >1.0 in men and >0.9 in women is abnormal. It
carries a high risk for coronary artery disease.
PATHOGENESIS OF METABOLIC SYNDROME
“The metabolic syndrome seems to have 3 potential etiological
categories:
a. Obesity and disorders of adipose tissue;
b. Insulin resistance; and
c. A constellation of independent factors (eg, molecules of hepatic,
vascular, and immunologic origin) that mediate specific
constituents of the metabolic syndrome.
d. Other factors—aging, proinflammatory state, and hormonal
changes—have been implicated as contributors as well.”
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INSULIN RESISTANCE
The most accepted theory for the development of  syndrome X is insulin
resistance.  Defect in the action of insulin causes insulin resistance.
Initially this will manifest as post prandial hyperinsulinemia which will
proress to preprandial elevated insulin levels. As the defect progresses,
eventually elevated blood glucose develop and may lead to diabetes. The
base metabolic abnormality responsible for the causation of  insulin
resistance is elevated free fatty acids. The source of circulating free fatty
acids is the adipose tissue and circulating lipoproteins.  Free fatty acids
released from adipose tissue are released into portal circulation and act
directly on the liver. increased free fatty acids cause insulin resistance
and insulin resistane further increase the free fatty acid level thereby
leading to a vicious cycle.
ELEVATED
FFAs
DOWNSTREAM
SIGNALLING
DEFECT
INSULIN
RESISTANCE
INCREASED
LIPOLYSIS
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Insulin normally inhibits lipolysis in the adipose tissue and increases the
activity of Hormone sensitive lipase . Final effect is t decrease the FFA
output from fat tissue. In insulin resistance, loss of inhibition of lipolysis
leads to increased FFA levels, which act on liver and lead to increased
VLDL production. Triglycerides also accumulate in the liver which may
lead to the development of fatty liver. As the syndrome advances, fatty
liver may progress to steatohepatitis , fibrosis and finally cirrhosis.
Excess FFA further cause propagation of insulin resistance by affecting
downstream signalling in insulin pathway.
MECHANISM OF INSULIN RESISTANCE AND DYSLIPIDEMIA
Mechanism of insulin resistance and dyslipidemia
Insulin resistance leads to increased elease of FFA in circulation,
which acts on liver and cause ncresased production of VLDL causing
elevated TGL. VLDL stimulates cholesterol esters exchange with LDL
and HDL. Apo A 1 dislodges from TGL rich HDL and deplete HDL. TGL
rich LDL undergo lypolysis leading to elevated small dense LDL.
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This loss of insulin sensitivity leads to defective insulin mediated
glucose uptake which cause hyperglycemia. FFA also accumulate in
various organs like muscle and liver.
Hyperleptinemia is commonly associated with MS. Studies indicate
leptin resistance may play a role in the development of MS. Leptin
suppress appetite and increases the basal metabolic rate and improves the
peripheral action of insulin.
Oxidative stress also has been proposed to play  a role as aging increases
the prevalence of MS.
Central obesity has a key role in the pathogenesis of metabolic
syndrome. Visceral adipose tissue ( VAT ) refers to fat cells located
within the abdominal cavity and it includes omental , mesenteric
retroperitoneal and perinephric adipose tissue .In lean individuals VAT
represents 20% of fat in men and 6% of fat in women . Obese individuals
have an expanded fat cell mass characterized by visceral adiposity. The
increase in insulin resistance with weight gain is directly related to the
amount of VAT.
NORMAL INSULIN ACTION:
In the fasting state approximately 85% of glucose production
is derived from the liver with remainder produced by the kidney.
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Metabolism of glucose by muscle requires insulin .In the fed state,
carbohydrate ingestion leads an increase in  the plasma glucose
concentration and stimulates insulin release from the pancreatic beta cell.
The resultant elevation in the  plasma insulin
1. Suppress hepatic glucose production
2. Stimulates glucose uptake by peripheral tissues
The majority of glucose that is taken up by peripheral tissues is disposed
in muscle, with only a small amount (4-5%) being metabolized by
adiposities.
Although the fat tissue is responsible for only a small amount of
total body glucose disposed, it plays a very important role in the
maintenance of body glucose homeostasis through the release of free
fatty acids (FFA) .Small increments in plasma insulin exert a potent
antilipolytic effect, leading to a marked reduction in the plasma FFA
level .The decline in the plasma FFA levels results in increased glucose
uptake in muscle and reduces hepatic glucose production.
Visceral fat cells have a high lipolytic rate which is especially
refractory to insulin .Increased lipolysis of fat results in elevation of
plasma FFAs and cause insulin resistance in muscle and liver and
impairs insulin secretion. Obese individuals have increased FFA levels
in their blood. FFAs are stored as triglycerides in muscle and liver and
the increased fat content correlates closely with insulin resistance in
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these tissues .Finally FFA released into the portal circulation drain into
the liver where they stimulate production of VLDL particles .
Visceral fat cells are active endocrine cells producing many
cytokines including leptin, interleukin 6, tumor necrosis factor alpha,
plasminogen activator inhibitor -1 (PAI-1) angiotensinogen, resistin and
CRP .These adipokines drain into portal circulation and reduce insulin
sensitivity in peripheral tissues.
VAT is also the source of anti inflammatory, anti atherosclerotic
adipokines known as adiponectin ,a hormone associated with increased
insulin sensitivity. obesity is associated with decreased levels of
adiponectin studies have abnormalities in adiponectin –insulin sensitivity
axis in non diabetic south Asians, which may be an important to
atherogenisis in this population. Raji et al showed lower levels of
adiponectin in Asian Indians.
Increased VAT may also leads to elevated level of cortisol, which
would increase insulin resistance .
Fat cells size is an important predictor of diabetes. Small newly
differentiated adipocytes are more insulin sensitive than large, lipid rich
fat cells. The smaller cells are able to take up glucose and store lipid . In
contrast, the larger cells have low rates of insulin stimulated glucose
uptake, less suppression of lipolysis and a higher rate of cytokine
16
production .Visceral fat cells tend to be larger and more metabolically
active than subcutaneous fat cells.
Dyslipidemia
Increased FFA act on liver and enhance VLDL production which lead to
hypertriglyceridemia. Hypertriglyceridemia is a perfect marker for
insulin resistance. As the degree of insulin defect increases, the
triglyceride levels increase proportionally. Apo CIII levels increase in
VLDL molecules which inhibit the peripheral lipoprotein lipase which
further increase the TGL levels.
Increased TGL is commonly associated with decreased HDL and
increased LDL.  TGL cause abnormality in the function of Cholesterol
Ester Transfer  Protein - CETP, which normally is responsible for
exchanging cholesterol and triglycerides between HDL, LDL and
VLDL. This abnormality leased to decrease in cholesterol content of
HDL and increased triglyceride content, which makes t highly sensitive
to hepatic lipase. This process leads to the production of small HDL
which is rapidly cleared by renal metabolism, ultimately leading to
reduced HDL.
In addition, LDL metabolism is also altered.  Hypertriglceridemia leads
to predominance of small dense LDL which have more atherosclerotic
properties.
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Glucose intolerance
Defect in insulin action leads to increased hepatic and renal
glycogenolysis and gluconeogenesis.  In addition impaired insulin
mediated glucose uptake by cells lead to hyerglycemia. Hyperglycemia
stimulates hyperinsulinemia, which compensates for insulin resistance.
As the abnormality progresses, compensatory mechanisms fail and
defective pancreatic beta cells action may lead to development of frank
diabetes which further increase the CAD risk.
HYPERTENSION
There is a definite relationship between insulin resistance and MS.
Insulin is a normal endogenous vasodilator. This mechanism is lost in
insulin resistance leading to vasoconstriction. Insulin also increases salt
resorption in the kidney thereby contributing to hypertension.
NADPH oxidase action in the adipose tissue releases oxygen free
radicals which may play a role in hypertension.
Increased proinflammatory cytokines in metabolic syndrome may also
contribute to hypertension
Hyperuricemia commonly seen in insulin resistance causes endothelial
dysfunction, decreased Nitric oxide levels which may further lead to
hypertension.
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CRITERIA FOR DIAGNOSING METABOLIC SYNDROME
There are three different criteria for diagnosing metabolic syndrome.
The National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATPIII)
“According to the third report of the National Cholesterol Education
Program (NCEP) Adult Treatment Panel III (ATPIII), adults to be
diagnosed with metabolic syndrome must have three or more of the
following:
1. Waist circumference >102 cm (40.2 in) in men and >88 cm (35.6 in)
in women
2. Serum triglycerides ≥150 mg/dl
3. Blood pressure ≥130/85 mmHg
4. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women
5. Fasting plasma glucose >6.1mmol/l (≥100 mg/dl)”
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The World Health Organization (WHO)
“On the other hand, definition of metabolic syndrome by the World
Health Organization (WHO), the individual has to either be diabetic, or
have , impaired fasting glucose (IFG) >5.6mmol/l, impaired glucose
tolerance (IGT), or insulin resistance and then have at least two of the
following:
1. Waist-to-hip ratio >0.90 in men or >0.80 in women or BMI> 30kg/m2
2. Serum triglycerides ≥150 mg/dl or HDL cholesterol <35 mg/dl in men
and <39 mg/dl in women
3. Blood pressure ≥140/90 mmHg
4. Urinary albumin excretion rate >20 mg/min or albumin-to-creatinine
ratio≥30 mg/g. (Microalbuminuria).
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International Diabetes Federation (IDF) [75]
“Central obesity (defined as waist circumference with ethnicity specific
values, if BMI is >30kg/m², central obesity can be assumed and waist
circumference does not need to be measured) AND any two of the
following:
1. Raised triglycerides : >150 mg/dL (1.7 mmol/L), or specific
treatment for this lipid abnormality.
2. Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males,
< 50 mg/dL (1.29 mmol/L) in females, or specific treatment for lipid
abnormality
3. Raised blood pressure: systolic BP >130 or diastolic BP >85 mm
Hg, or treatment of previously diagnosed hypertension.
4. Raised fasting plasma glucose :( FPG)>100 mg/dL (5.6 mmol/L), or
previously diagnosed type 2 diabetes. If FPG >5.6 mmol/L or 100
mg/dL, OGTT Glucose tolerance test is strongly recommended but
is not necessary to define presence of the Syndrome.”
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Ethinic specific values for cut off for waist circumference:
Metabolic Syndrome as a Predictor of CVD
People with metabolic syndrome are at expanded danger for CHD. In
Framingham, the metabolic syndrome alone anticipated ≈25% of all
new-onset CVD. Without diabetes, the metabolic syndrome by and large
did not raise 10-year hazard for CHD to >20%; this is the edge for ATP
III's CHD hazard comparable. Ten-year hazard in men with metabolic
syndrome for the most part went from 10% to 20%. Framingham ladies
with metabolic syndrome had moderately few CHD occasions over the
span of the 8-year development; this was expected to some extent to the
high extent of ladies who were under 50 years old. In spite of the fact
that the metabolic syndrome in these ladies had all the earmarks of being
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joined by higher danger for CVD/CHD, the certainty interim was wide,
and contrasts between those with and without metabolic syndrome were
not factually critical. Of note, the 10-year hazard for CHD in most ladies
did not surpass 10%.
Framingham investigators then examined whether the metabolic
syndrome carries incremental risk beyond the usual risk factors of the
Framingham algorithm. Analyses were carried out both including and
excluding patients with diabetes. Several models were tested. Results
were compared as C statistics. The C statistic is the probability that the
model used will place a person in the right order, giving the higher
probability to the one who develops the disease than to the one who does
not. Some investigators consider this approach to have limitations,
particularly because of the high contribution of age alone to the C
statistic. Nonetheless, this is a standard method for evaluating the power
of adding new risk factors to multiple–risk factor equations.
A late meta-analysis by Gami et al. that included 36 distinct reports
found that the general relative risk for CVD and demise for people with
the Metabolic syndrome was 1.78 (95% CI, 1.58–2.00). In another
report, U.S. grown-ups without earlier CVD from the NHANES were
taken after for roughly 13 yr. For those with the metabolic syndrome, the
danger variable balanced corresponding risks relapse for CHD mortality
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was multiplied. Utilizing the Framingham database, the age-balanced
relative dangers for CVD and CHD in men with the Metabolic syndrome
were 2.88 and 2.54, individually, with those in ladies being somewhat
lower (2.25 and 1.54, separately). The nearness of the metabolic
syndrome in patients with prior CHD is likewise connected with an
expanded danger for CVD occasions and mortality. Obese people and
those with prior diabetes additionally have a multiplying of CVD danger
when the Metabolic syndrome is available. McNeil et al. found that more
established people (mean age, 72 yr) with the Metabolic syndrome were
20–30% more prone to encounter a CVD occasion than those without..
As one would expect, the more constituents or components of the
Metabolic syndrome that are available, the more prominent the CVD
hazard. There are only a couple of special cases to these discoveries..
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER),
another investigation of more established people matured 70–82 yr,
likewise neglected to demonstrate a relationship between the Metabolic
syndrome and expanded danger of CVD. WC, in any case, was not
measured in PROSPER, and HDL-C and diastolic pulse (unobtrusively)
were the main constituents that anticipated occurrence CVD; neither
BMI, nor systolic circulatory strain, LDL-C, or triglycerides were
connected with CVD hazard. Since the prevalence of Metabolic
syndrome levels in the 60s, this may not be a study that determines the
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Metabolic  syndrome/CVD result discussion. A study in an accomplice
of non diabetic American Indians. CAD rates were entirely low by and
large in this companion, as has been appeared in different investigations
of American Indians, possibly affecting the ability to recognize contrasts.
At long last, in an investigation of people with known stable CHD, the
Metabolic syndrome was connected with expanded aggregate mortality
and CVD mortality in ladies yet did not give off an impression of being
connected with overabundance danger of CVD mortality in men. The
meta-analysis by Gami et al. found the WHO definition to be associated
with slightly greater risk than the NCEP:ATPIII definition (2.06 vs.
1.67).
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Type 2 diabetes mellitus
The prevalence of T2D has tripled in the last 30 yr. In spite of the fact
that insulin resistance is viewed as the sign of prediabetes, deformities in
insulin emission are viewed as the key pathophysiological normal for
T2D. In spite of the fact that T2D is a heterogeneous disorder, most
patients with T2D have insulin resistance and the Metabolic
syndromebefore onset of T2D. Actually, insulin resistance,
hyperinsulinemia, dyslipidemia, and obesity go before the movement to
T2D in 75 to 85% of patients.
CONDITIONS SEEN IN ASSOCIATION WITH METABOLIC
SYNDROME:
NONALCOHOLIC FATTY LIVER DISEASE
Nonalcoholic fatty liver disease (NAFLD) range from mild steatosis to
NASH to cirrhosis. A diagnosis of NAFLD can be made in patients with
raised liver enzymes and/or fatty liver by imaging without different
reasons for liver sickness, despite the fact that a conclusive
determination must be made by liver biopsy. The prevalence of NAFLD
extents from 3 to 36% of the overall public, contingent upon how it is
characterized. It has been recommended that 95% of corpulent people
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and up to 70% of those with T2D have some type of NAFLD. The
prevalence of NAFLD is additionally expanded in youngsters with
obesity and insulin resistance . In those patients with the Metabolic
syndrome, liver fat substance is essentially expanded up to 4-fold higher
than those without the Metabolic  syndrome, and the frequency of
NAFLD has appeared to be expanded 4-fold in men and 11-fold in ladies
with the Metabolic  syndrome
POLYCYSTIC OVARIAN SYNDROME (PCOS) :
It is a clinical syndrome that is connected with anovulation, androgen
abundance, and insulin resistance. These patients are at increased risk for
T2D  and CVD.. There have been civil arguments on whether PCOS
may in certainty be in the continuum with the Metabolic  syndrome. The
Metabolic syndrome is normal in ladies, particularly corpulent ladies,
with PCOS. The prevalence of PCOS is likewise ascending, with rates
reported as high as 28% in overweight/stout ladies.. The ovary,
hypothalamic-pituitary pivot, and insulin resistance all are thought to
have a part in this condition. Ladies with PCOS unmistakably have a
higher prevalence of CVD danger elements.
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OBSTRUCTIVE SLEEP APNEA
Obstructive sleep apnea (OSA) is a potentially serious consequence of
obesity and is associated with increasing BMI. There is also an
association between insulin resistance and OSA. OSA has also been
shown to be associated with increased inflammation and reduced
adiponectin concentrations. Individuals with OSA are more likely to
have the features of the Metabolic syndrome than those without OSA,
even when adjusted for obesity. In addition, disordered sleep in general
is associated with weight gain and insulin resistance. Some have even
suggested that OSA should be considered as a manifestation of the
Metabolic syndrome.
HYPOGONADISM
There is a relationship between the Metabolic syndrome and male
gonadal and erectile dysfunction. Men with the Metabolic syndrome
seem to have a more prominent prevalence of hypogonadism. Moreover,
components of the Metabolic syndrome enhance with testosterone
substitution. The Metabolic syndrome has additionally been appeared to
be autonomously connected with a more prominent prevalence of
erectile dysfunction.
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LIPODYSTROPHY
Lipodystrophies are a group of conditions characterised by fat wasting.
The pathogenesis is complicated. Patients with this condition have
extreme insulin resistance, making these people at danger for diabetes,
fatty liver, cardiovascular disease. Anti retroviral therapy has been
shown to dramatically reduce the prevalence of lipodystrophy corrects
the deranged metabolic parameters.
MICROVASCULAR DISEASE
Patients with the Metabolic syndrome are at more serious danger for
microvascular disease free of diabetes. Around 8–10% of people with
IFG and IGT yet without diabetes, a large portion of whom have the
Metabolic  syndrome, have retinopathy. The Metabolic syndrome has
additionally been appeared to be connected with an expanded danger of
kidney dysfunction and microalbuminuria. Besides, the Metabolic
syndrome has been observed to be connected with expanded danger for
neuropathy. For those people with diabetes, the Metabolic syndrome
seems, by all accounts, to be connected with expanded danger for a wide
range of microvascular infection despite the fact that a late post hoc
investigation of the United Kingdom Perspective Diabetes Study did not
observe the Metabolic syndrome to be connected with a more serious
danger for microvascular illness in people with T2D.
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TREATMENT
Obesity And  Adipose Tissue - Targets For  Treatment
ATP III prescribed that obesity be the essential focus of intercession for
metabolic syndrome. In the first place treatment ought to be weight
reduction fortified with expanded physical action. Weight reduction
brings down serum cholesterol and triglycerides, raises HDL cholesterol,
brings down circulatory strain and glucose, and diminishes insulin
resistance. Weight lessening can diminish serum levels of CRP and
PAI- 1.Obesity contributes altogether to improvement of the metabolic
syndrome in the all inclusive community.
Insulin Resistance as Target of Therapy
On the off chance that insulin resistance, whether primary or secondary
to obesity, is in the chain of causation of metabolic syndrome, it would
be an appealing target. Surely, weight decrease and expanded physical
action will diminish insulin resistance. Two classes of medications are
right now accessible that decrease insulin resistance. These are
metformin and insulin sensitizers, for example, thiazolidinediones
(TZDs).
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Metformin has for some time been utilized for treatment of type 2
diabetes. In UKPDS, metformin clearly lessened new-onset CHD in
corpulent patients with diabetes. In the Diabetes Prevention Program,
metformin treatment forestalled (or postponed) onset of type 2 diabetes
in people with IGT. At present, metformin can't be suggested
diminishing danger for CVD in people with the metabolic syndrome.
TZDs right now are endorsed for treatment of type 2 diabetes. They
lessen insulin resistance, positively alter a few metabolic danger
elements. In this manner, regardless of guarantee, TZDs can't be
prescribed at present for anticipating CVD in patients with either
metabolic syndrome or diabetes.
THERAPEUTIC INTERVENTIONS
Diet.
a. Carbohydrate.
Currently, the United States Department of Agriculture (USDA)
recommend a carbohydrate intake of 45–65% of total caloric intake
(USDA, 2005). This recommendation is appropriate for most
populations because total carbohydrate consumption has not been shown
to be associated with the development of T2D or the Metabolic
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syndrome. Due in part to the recent rise in the popularity of low-
carbohydrate diets, there has been interest in the effect of carbohydrate
intake on serum lipid levels. Investigations into this question have
consistently reported that carbohydrate intake is positively associated
with total cholesterol, LDL-C, and triglycerides and negatively
associated with HDL-C. In addition, lower carbohydrate diets have been
associated with improved carbohydrate metabolism in those with insulin
resistance and/or T2D. Although weight loss has been shown to be
greater with lower carbohydrate diets in the short term, the effects on
long-term weight loss have been mixed.
Dietary carbohydrate can be placed into two categories: simple and
complex. It is the latter that should comprise the bulk of the carbohydrate
intake, whereas simple carbohydrates, especially in the form of added
sugars, should be limited (USDA, 2005). Common sources of added
sugars in the diet include soft drinks, cakes, cookies, pies, fruit drinks,
dairy desserts, and candy. Although added sugars are chemically
identical to naturally occurring simple sugars (e.g., sugars found in fruit),
concern is warranted regarding the lack of nutrients found in foods laden
with added sugars. It has been shown that individuals who consume a
greater percentage of calories as added sugars consume significantly less
vitamins and minerals.
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b. Protein.
Information in regards to proper protein admissions for patients with the
Metabolic syndrome are scanty. The ARIC concentrate, in any case, as
of late found that meat admission was connected with Metabolic
syndrome frequency. Except for patients with nephropathy, a protein
admission inside the proposals for the overall public is satisfactory: a
protein admission of 10–35% of aggregate caloric admission is
suggested by the IOM.
c. Fat.
Saturated fat has reliably been appeared to be emphatically connected
with fasting insulin levels. The substitution of unsaturated fats for
saturated fats in the eating routine has been indicated either to have no
impact on or to enhance insulin affectability. Given the watched
relationship between saturated fat admission and insulin levels, it is
judicious to prescribe a decrease in saturated fat admission (<7% of
caloric admission) and in increment in the unsaturated fats, particularly
linoleic (5–10% of caloric admission) and α-linolenic (0.7–1.6% of
caloric admission), as is advanced by the 2005 USDA Dietary
Guidelines. Both serum cholesterol and general CVD hazard have been
appeared to be enhanced by kind of dietary fat, i.e., a lessening in soaked
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fat and an expansion in unsaturated fat, more so than aggregate fat
admission. The Nurses' Health Study agents reported that a 5%
expansion in saturated fat admission was connected with a 17%
increment in coronary danger, while monounsaturated and
polyunsaturated fat admissions were contrarily identified with coronary
disease.
d. Sodium.
Notwithstanding the impacts of eating regimen on weight reduction,
other life changes can significantly affect blood presssure. An
unmistakable positive affiliation has been appeared between sodium
admission and circulatory strain, with intemperate sodium consumption
connected with hypertension. Sodium limitation has been appeared to be
a critical system in the prevention and treatment of hypertension. The
Dietary Approaches to Stop Hypertension (DASH) diet demonstrated
that lower sodium admission diminished circulatory strain in patients
with high-ordinary pulse and mellow hypertension. Besides, sodium
limitation has likewise been connected with diminished CVD occasions
and congestive heart disappointment. Rules in this manner suggest that
day by day sodium admission ought to be confined to close to 65–100
mmol. Notwithstanding sodium limitation, expanded potassium
admission has additionally been appeared to enhance circulatory strain,
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particularly in the setting of high sodium consumption. Rules have
prescribed the admission of nourishments advanced with potassium, for
example, products of the soil, with an objective of 90–120 mmol of
potassium for every day.
Dietary admission obviously affects the greater part of the constituents
of the Metabolic  syndrome. Albeit every case ought to be dealt with
exclusively, it is reasonable to suggest an eating routine low in saturated
fat, higher in unsaturated fats, high in complex sugars, and low in
sodium.
It is entrenched that weight reduction is advantageous for treating the
majority of the constituents of the Metabolic syndrome, including
unreasonable adiposity, dyslipidemia, hypertension, insulin resistance,
and hyperglycemia. The greatness of weight reduction need not be
intense; the Finnish Diabetes Prevention Study demonstrated that way of
life mediation with humble weight reduction essentially diminished the
prevalence of the Metabolic syndrome(OR, 0.62; 95% CI, 0.40–0.95)
contrasted and the control bunch. A 41% decrease in the frequency of the
Metabolic syndromewas likewise seen with the escalated way of lifestyle
intervention  of the DPP[121]. Furthermore, a weight reduction as little
as 5–10% of body weight can fundamentally diminish triglycerides and
increment HDL-C. Moreover, both hypertensive people and people at
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danger for hypertension can see a noteworthy decrease in pulse with an
unassuming weight reduction. Fasting blood glucose, insulin, and
hemoglobin A1c can likewise be diminished with humble weight
reduction; Strikingly, the DPP exhibited that weight reduction was the
number 1 indicator of diminishment in the rate of diabetes. For each
kilogram of weight reduction, the danger of diabetes advancement was
diminished by 16%.
Aerobic Exercise And Insulin Resistance.
Exercise enhances glucose metabolism by improving glucose transport
and insulin activity in working skeletal muscle. This intense impact of
activity on insulin-mediated glucose uptake does not seem to hold on
past 24 h after the last episode of activity. American College of Sports
Medicine suggestion to practice no less than 30 min/d most days of the
week. There is proof to recommend that maybe oxygen consuming
activity preparing ought to be joined by weight reduction for a
determined impact on glucose resilience and insulin activity past the
prompt post exercise impacts.
Aerobic Exercise And Dyslipidemia.
Current NCEP:ATPIII guidelines recommend LDL-C reduction as the
primary treatment goal for CVD risk reduction, Although aerobic
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exercise training increase HDL-C and to decrease triglycerides, results
are mixed for an effect on LDL-C.
Aerobic Exercise And Hypertension.
It is well known that aerobic exercise decrease the mean blood pressure
both in obese and non obese individuals and is beneficial in patients with
metabolic syndrome
CORONARY ARTERY DISEASE
Coronary artery disease is an important cause of mortality all over the
world, in fact it is the leading cause of mortality. The rate of CAD varies
widely among different populations. The CAD prevalence among Asian
Indians who are staying overseas are 50 to 400% higher than the people
of other ethnicity. India is now facing a huge epidemic of coronary artery
disease and the CAD prevalence in Indians is more than fourfold higher
than that of Americans.
Prevalence of CAD
In India the prevalence of CAD was 1.17 million in the year 1990. It was
1.59 million in 2000. By the year 2010, the prevalence rose to 2.03
million
The prevalence of CAD is twice in urban areas than in rural areas. It is
higher in southern India than northern India. There is a higher rate of
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abdominal adiposity among urban areas than rural areas.  This increased
prevalence of CAD in Asians is because of inherited hereditary factors.
CORONARY CIRCULATION
Anatomy of coronary arteries
The heart derives its blood supply from the two coronary arteries namely
the right and the left.
Right coronary artery originates from the anterior aortic sinus and then it
passes behind the right atrial appendage and the right ventricular
infundibulum. It gives branches to both the atria and the ventricles as it
passes downwards vertically in the atrio-ventricular groove. The
marginal branch, a the inferior border of heart, passes to the left along
the  right ventricle and the main artery runs posteriorly. The inferior
inter-ventricular branch arises from the inferior surface. This large artery
runs along the posterior  inter-ventricular groove in the posterior surface.
The left coronary artery originates from the left posterior sinus of aorta
and divides immediately as anterior descending artery and  circumflex
artery which run into anterior inter-ventricular groove and the atrio-
ventricular sulcus, respectively.  The left circumflex passes through the
lateral wall of the heart and supplies the posterior ventricle.
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Distribution of the coronaries
Right coronary artery supplies anterior anterior right atrium and the right
ventricle except at the upper margin of anterior surface, where it is
supplied by anterior interventricular arteries.
Left ventricle is supplied by the  LCA except for a narrow strip of the
diaphragmatic surface which is supplied by inferior interventricular
artery. It supplies left atrium and its appendage also with the posterior
surface of right atrium.
SA node and AV node is supplied by the right coronary artery in 60%
and  90% respectively. The left coronary  supplies the remaining
percentage of cases. The inferior interventricular artery supplies the AV
node and His Bundle.
Dominant arteries
In 67% cases, right coronary artery is dominant while in 15%, the left
coronary is dominant.  In another 18% there is a balanced coronary
arterial pattern.
Normal coronary blood flow
The coronary circulation receives about 4.5% of the cardiac output at
rest. During exercise it increases y four to five fold.
39
Physiology of coronary circulation
Physiologically both the coronary arteries are end arteries, inspite of
anastomoses. The innermost 75- 100 microns of endocardium obtains
nutrition directly from blood in the cardiac chambers.
Control of coronary blood flow
1. Prime controller - local myocardial metabolism
2. Neuronal control
Local myocardial metabolism : the rate of blood flow
increases with increase in vigour of contraction. The factors
responsible are : Oxygen demand
As oxygen extraction is complete in resting state of heart,
increase in oxygen demand has to be met with by increasing
the coronary flow. This is achieved by
 Vasodilator theory : hypoxia will release several vasodilator
substances from cardiac myocyte which increases the blood flow
rate
 Adenosine from ATP
 Hydrogen ion
 Carbon dioxide
 Potassium  ion
 Bradykinin and
 Prostaglandins
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 Arterial smooth muscle relaxation theory: decrease in oxygen
supply leads to anoxia of coronary arterial smooth muscle cells,
which lose the tone leading to dilatation. Oxygen consumption
depends upon following factors
 Greater the work, the greater is consumption of
oxygen, within physiological limits
 Oxygen consumption is directly proportional to peak
myocardial muscle tension which depends upon
arterial pressure and size of the ventricular cavity
Neuronal control
Indirect:
Sympathetic stimulation of heart increases the rate and cardiac
contractility, through the local metabolic mechanisms and hence
increases the coronary flow. Parasympathetic stimulation decreases the
heart rate and causes coronary vasoconstriction.
Direct effect:
Epinephrine and nor epinephrine directly act on their receptors in the
coronary vessels an d cause vasoconstriction.
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EPIDEMIOLOGY OF CORONARY HEART DISEASE
Coronary artery disease (CAD) is the foremost cause of mortality in
individuals above 40 years of age throughout the world.
In the America it is estimates reveal that individuals above 30years of
age have a prevalence of CAD of 213 per 100,000 people.
Accurate data on the prevalence of CAD in India are not available.
Recent surveys in small population groups in different geographical
areas estimate a prevalence of about 5% in urban and a much lower
prevalence in rural population.
The pattern of CAD (India) is reported to as follows:
1. Males  are more affected than females
2. Hypertension and diabetes accounts for 40% of all cases
3. Heavy smoking is particularly prevalent.
4. Other factors like high fat diet and sedentary lifestyle.
5. Alcohol consumption in large quantities increases the risk  of
atherosclerosis.
The prevalence of CAD in India has increased greatly in the last three
decades and younger persons are also prone to the disease.
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RISK FACTORS FOR CAD:
Risk factors for CAD can be broadly divided into modifiable and
non modifiable risk factors .Modifiable risk factor can also be divided
into lipid and non lipid factors.
NON MODIFIABLE RISK FACTORS:
1. AGE:
Male > 45 years
Females >55 years
2. FAMILY HISTORY OF PREMATURE CAD:
Male first degree relative <55 years
Female first degree relative <65 years
3. Male sex
MODIFIABLE-NONLIPID RISK FACTORS :
1. Diabetes
2. Smoking
3. Lifestyle risk factors –obesity –BMI>30kg/meter square
- Physical inactivity
-Atherogenic diet
4. Hypertension
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MODIFIABLE –LIPID RISK FACTORS:
a) Total cholesterol > 200 mg/dl
b) Triglyceride >150 mg/dl
c) 3 Apo b >100mg/dl
d) HDL<40mg/dl in males and <50mg/dl in females
e) LDL >100 mg/dl
NEW EMERGING RISK FACTORS:
1. Impaired fasting glucose
2. Homocysteine >15
3. Prothrombotic factors
4. Proinflammatory factors
LIPID ABNORMALITIES OF CAD :
HDL is the only known carrier of cholesterol from
peripheral tissues to liver i.e. reverse cholesterol transport ,which is a
protective mechanism against atherogenesis .Each 1mg HDL cholesterol
is estimated to decrease CAD by 2-4% .HDL >60 is a “negative
“coronary risk factor. A low HDL is associated with increased risk of
CAD even if   TGL and TC levels are not elevated .A 10 mg /dl fall in
HDL confers the same risk for CAD as 30mg/dl increase in LDL .In
general Indians had HDL level > 5 mg /dl lower than Europeans and
American whites .A study on Asian Indians living in the united states
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found that 54% of men had an HDL level below 40 mg/dl and 68% of
women had levels below 50 mg/dl .South Asians not only have HDL
level lower but also have higher concentration of small ,less protective
HDL particles ,which suggests impaired reverse cholesterol transport .
HIGH TRIGLYCERIDE:
About 95% of TG in body is stored in adipose tissue as
glycerol fatty acids and monoglycerides. An 88mg/dl increase the
relative risk of CAD by 30% in men and 75% in women .Paris
prospective study and NCEP ATP III guideline has accepted TG as an
important risk factor for CAD .Johnson SL et all .In STRIDE had
noticed higher significance of TG in female CAD .The same was noted
by Gupta et all and Acarteik et all. Low TG and high HDL level have a
lower risk of CAD, but this profile is uncommon among Asian Indians.
TOTAL CHOLESTEROL:
It is a strong risk factor for CAD .At any given total
cholesterol or LDL level, Asian Indians had more risk than whites.
Recent study shown that 8 fold higher CAD mortality with increase in
TC from 160 to >280mg/dl .Therefore Asian Indians should be treated
aggressively .The optimum level of total cholesterol appears to be
150mg/dl for Asian Indians.
TC/HDL >4.5 has a higher risk, ratio < 3.5 is a clinical goal for CAD
prevention.
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LDL CHOLESTEROL:
Although LDL levels of south Indians tends to be
higher, the particle size tends to be smaller. Small particles through
increased susceptibility to oxidation are more atherogenic than larger
particles.
LIPOPROTEIN (a) :
Is a variable of LDL and a strong risk factor. It
appears to be the link between the atherosclerosis and thrombosis. It is
highly thrombogenic and antifibrinolytic .It is denoted as” deadly
cholesterol”
Their levels are governed by age, gender, diet, and other environmental
factors childhood levels of Lp (a) is a future marker of CAD. Threshold
level is >30 mg/dl and the risk increases with the level between 15-20
mg/dl.
PHYSICAL INACTIVITY:
Regular physical exercise reduces myocardial
oxygen demand and increases the exercise capacity.
Benefits include
-Enhances insulin sensitivity
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-decreases adiposity and diabetes
- lowers blood pressure
-improvement of dyslipidemia, plasma rrheology , vascular
inflammations.
TOBACCO ABUSE:
Single most important risk factor .Smoking >10
Cigarettes or beedi per day is associated with high risk of MI .It affects
atherothrombosis ,enhance oxidation of LDL and impairs coronary artery
dilatation .It has adverse hemostatic and inflammatory activity including
increased levels of hs CRP ,intercellular adhesion molecule -1 (ICAM-1)
,Fibrinogen ,homocysteine ,and spontaneous platelet aggregation
.Smokers have increased risk for coronary spasm and ventricular
arrhythmias ,Women are affected by passive smoking .The risk of CAD
begins to decline with the cessation of smoking  within 3-5 years .
PSYCHOSOCIAL FACTORS:
Depression, hostility, and anger and low social
support are associated with CAD. Type A personality is not associated
with CAD.
EMERGING CARDIC RISK FACTORS:
Lipoprotein (a), apo lipoprotein B,
homocysteine, plasminogen activator inhibitor 1, pro inflammatory
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adipokines levels tend to be high in south Asian .Micro albuminuria is
considered as a independent risk factor .
ASIAN INDIAN PARADOX:
High rates of CAD in Asian Indians are
accompanied by low rates of conventional risk factor except for diabetes.
For Asian Indians physical activity was high and saturated fat
consumption was low.
PATHOGENESIS
Atherosclerosis is a disease primarily affecting the intimal layer of the
elastic arteries. Some arterial beds are more affected than others, for
unknown reasons.  Coronary, carotid and renal arteries are more
commonly involved. The arteries of the lower limb also commonly
involved leading to peripheral vascular disease.
Atherosclerotic pass through several stages and evolve slowly
through several years. Histologically the earliest lesion to
develop is the subendothelial accumulation of foam cells, which
are lipid laden macrophages and associated T  cell lymphocytes.
This lesion is known as Fatty Streak. Fatty streaks are usually
asymptomatic and do not lead to stenosis.
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Atherosclerotic plaque
EVOLUTION OF THE ATHEROSCLEROTIC LESION
Autopsy studies have revealed that fatty streaks arise in the aorta at the
end of the first decade of life. They appear in the coronaries by the the
second decade and start to appear in the cerebral blood vessels by the
third decade. With time, these lesions gradually progress and the core of
the lesion become necrotic, containing cellular debris, cholesterol
crystals and inflammatory cells, particularly lipid laden foam cells. This
necrotic core gets surrounded on the luminal aspect by a fibrous cap
49
which is lined  by endothelium. The fibrous cap is  made up of vascular
smooth muscle cells with extensive collagen and matrix. Inflammatory
cells are also present in the cap especially at the shoulder region, where t
cells, mast cells, macrophages tend to accumulate. As the lesions
advance they become increasingly complex with evidence of
calcification, new vessel formation, erosion and ulceration. The
composition of the atheromatous plaque is thus complex and the
progression and outcome depends on the interaction between various
types of cells in the plaque.
Atherosclerosis is regarded as a dynamic disease which is progressive
and a result of combination of endothelial dysfunction and inflammation.
The vascular endothelium has the ability to sense any change in the shear
stress and respond by synthesising and releasing  mediators of vascular
tone.  Vascular homeostasis depends upon the balance between
endothelium derived relaxing factor and vasoconstricting agents. When
this balance is disturbed by inflammation and other traditional
cardiovascular risk factors, the vessels become susceptible to
atherosclerosis. Inflammatory mediators play a critical role in the
initiation, propagation  and ultimate rupture of the atherosclerotic lesion.
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Evolution of atherosclerotic  plaque
Endothelial cell activation is an important feature of atherosclerosis. The
activated endothelial cells express Vascular cell Adhesion Molecule 1
(VCAM 1), which cause leukocyte attachment and migration. Monocyte
adhesion is a critical event for atherosclerosis. Cytokines oxidised low
density lipoproteins present in the extracellular matrix and infectious
agents like Chlamydia and cytomegalovirus cause endothelial cell
activation.
51
Steps in the formation of atherosclerotic plaque
Endothelial dysfunction
There is a correlation between atherosclerotic risk factors and
endothelial function. LDL, especially oxidised LDL is potent endothelial
cell inhibitor of nitric oxide release and causes NO inactivation and
superoxide production. Endothelial dysfunction is characteristically seen
with elevated serum cholesterol. Cholesterol reduction improves the
endothelial function and decrease cardiac mortality and morbidity in
several studies. Increasing age, elevated bood pressure, diabetes mellitus,
smoking and estrogen therapy all modify the endothelial function.
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Inflammation and atherothrombosis
There is growing evidence of a link between inflammation and
atherothrombosis.  The endothelial cells express increased adhesion
molecules like VCAM 1 which lead to increased leukocyte influx.
Inflammatory processes all lead to initiation and evolution into advance
atherosclerotic plaques which lead to thrombotic complications. The
activated macrophages produce proteolytic enzymes which degrade the
collagen of the fibrin cap, rendering the cap weak , thin and susceptible
to erosion and rupture.
Cellular interaction and lesion stabilisation
Atherosclerotic plaque can manifest  in one of two ways. Foamy
macrophages undergo apoptosis in the presence of high concentration  of
oxidized LDL. The cellular remnant become incorporated into the lipid
rich core. As the plaque size increases, it leads to reduction in the
luminal area. At times of increased demand for blood flow, this may lead
to cardiac ischemia such as angina. More dangerous, if the fibrous cap of
the lesion disrupts, exposure of the thrombogenic matrix lead to
thrombosis of the vessel. Depending on the factors like collateral blood
flow, extent of the thrombus and degree of fibrinolytic activity, the end
result may be arterial occlusion and myocardial necrosis.
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Characteristics that are predictive of high risk for plaque rupture are
1. Thin fibrous cap
2. High inflammatory cells  to vascular smooth muscle cells
3. Lipid core that occupies >50% of plaque volume
Inflammatory cells in the plaque promote plaque rupture by numerous
mechanisms. Activated T  cells produce pro- inflammatory cytokines
like IFN that stimulate VSMC proliferation and inhibit matrix synthesis.
Macrophage derived inflammatory mediators like IL -1, and TNF alpha
cause depletion of VSMC due to their cytotoxic effects, leading to
unstable plaque formation.
Activated macrophages can induce apoptosis of VSMC by direct
cytopathic effects, due to the secretion of variety of matrix metallo-
proteinases that degrade the matrix component of the fibrous cap by
proteolysis of matrix. The production of these enzymes is up regulated
by inflammatory mediators.
Plaque disruption
Atherosclerotic plaque when ruptured can lead to thrombus formation
and lumen occlusion. This can be due to either erosion  of endothelial
cells lining the fibrous cap or rupture of the plaque with exposure of
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thrombogenic matrix, leading to the formation of a platelet rich
thrombus. Platelet activation may lead to triggering of the clotting
cascade, thrombus formation and occlusion of the vessel. Upto 70% of
the plaques may cause high grade stenosis and may contain histological
evidence of previous subclinical rupture and subsequent healing.
Plaque rupture, thrombosis, and healing
PREVENTION OF CAD IN ASIAN INDIANS:
i. Lifestyle modification such as increased physical activity and
reduced calorie intake particularly saturated fat should begin early
in life.
ii. Consumption of all tobacco products should be eliminated.
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iii. Screening methods such as waist circumference should be
measured rather than WHR, BMI.
iv. Assessment of fasting glucose and lipid profile are essential.
v. Reduction of abdominal obesity through lifestyle measures can
improve all components of the metabolic syndrome and likely
delay the development of both diabetes and atherosclerosis.
vi. Appropriate drug therapy should be considered for all lipid
abnormalities for the risk factors abnormalities which do not
respond to lifestyle modification.
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MATERIALS AND METHODS:
STUDY POPULATION:
The present study is conducted on patients admitted with a diagnosis of
AMI to the Coronary Care Unit (CCU) of Government Rajaji Hospital,
Madurai during the period of  February 2016 to July 2016.
INCLUSION CRITERIA:
1. All patients admitted  with a diagnosis of AMI to the Coronary
Care Unit (CCU) of  Government Rajaji Hospital with
2. Age < 45 years
3. Acute myocardial infarction is defined as at least two of the
following: prolonged chest discomfort, typical
electrocardiographic changes, or elevated cardiac troponin
levels, as outlined by the Joint European Society of
Cardiology/American College of Cardiology Committee
Exclusion criteria:
1. Rheumatic heart disease
2. Congenital heart disease
3. Severe anemia/ chronic kidney  and liver disease
4. Cocaine abuse
5. Lack of definitive MI criteria
6. Age > 45 years
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ANTICIPATED OUTCOME:
High prevalence of metabolic syndrome in young patients with acute
myocardial infarction
DATA COLLECTION:
A previously designed proforma is used to collect the demographic
and clinical details of the patients. A complete clinical examination
will be done.
Demographic data obtained from all patients include age, gender,
weight, height, waist circumference, and information on risk factors such
as diabetes, hypertension, smoking status, and a family history of
vascular disease. Smoking status was documented. The presence of
previously diagnosed diabetes was noted, as well as the mode of therapy
(diet alone, oral hypoglycaemic agents or insulin)
Blood pressure is measured twice in the supine position from right hand,
using a mercury sphygmomanometer. Waist circumference (WC) is
measured at the widest diameter between the xiphoid process of the
sternum and the iliac crest. Serum lipids and blood sugar were measured
by taking a sample of 5 mL blood from the right brachial vein after 12 h
overnight fasting. The blood samples were sent to central lab of
Government Rajaji Hospital.
Additional clinical data on complications encountered from hospital
admission until discharge were collected, and included events such as
58
sustained ventricular arrhythmias (ventricular tachycardia/ventricular
fibrillation) requiring intervention, complete heart block, cardiac failure,
cardiogenic shock, recurrence of angina or MI and death, as well as
information on angiographic results and revascularisation procedures
such as angioplasty.
According to the new IDF definition, the metabolic syndrome is defined
as :
“Central obesity (defined as waist circumference ≥ 90cm for Asian
Indian men and ≥ 80cm for Asian Indian women)
Plus any two of the following four factors:
• Raised TG Level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for
this lipid abnormality
• Reduced HDL Cholesterol: < 40 mg/dL in males and < 50
mg/dL in females, or specific treatment for this lipid abnormality
• Raised Blood Pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm
Hg, or treatment of previously diagnosed hypertension
• Raised Fasting Plasma Glucose (FPG) ≥ 100 mg/dL, or
previously diagnosed type 2 diabetes.”
DESIGN OF STUDY:
Cross sectional study
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PERIOD OF STUDY:
February 2016 to July 2016 (6 months)
COLLABORATING DEPARTMENTS:
Department Of Cardiology
Department Of Biochemistry
ETHICAL CLEARANCE: Applied for
CONSENT: Individual written and informed consent.
ANALYSIS: STATISTICAL ANALYSIS.
CONFLICT OF INTEREST: NIL
FINANCIAL SUPPORT:  SELF
PARTICIPANTS:
Patients with age< 45years, admitted  with a diagnosis of AMI to the
Coronary Care Unit (CCU) of  Government Rajaji Hospital,  Madurai
during the period of  February 2016 To July 2016.
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LABORATORY INVESTIGATIONS :
Overnight fasting blood sugar, and lipid profile were measured. The
blood sugar was measured using the glucose oxidase and peroxidase
method. In lipid profile total cholesterol was measured using the
cholesterol oxidase peroxidase method. The triglyceride was measured
using the glucose 3 phosphate oxidase-peroxidase method. Cholesterol in
the supernatant is measured after precipitation of apo-B containing
lipoprotein by polyethylene glycol to determine the HDL cholesterol.
LDL cholesterol is estimated by using the Friedewald formula and this
formula appears to be the most practical and reliable method for
determining LDL-cholesterol in clinical practice.
LDL- cholesterol=Total cholesterol-[HDL+(Triglyceride/5)]
VLDL is estimated by dividing the plasma triglyceride by 5 reflecting
the ratio of cholesterol to triglyceride in VLDL particles.
Limitations of the study:
1. Small number of subjects.
2. Single centre study.
3. Only the one timed blood pressure was measured.
4. Direct LDL measurement was not done, measured only by Friedwald
formula.
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RESULTS AND INTERPRETATION
After applying the inclusion and exclusion criteria 62 cases were
selected for the study. The age distribution is as follows,
GRAPH 1: SHOWING THE SEX DISTRIBUTION OF THE
STUDY POPULATION
GRAPH 2: SHOWING THE AGE DISTRIBUTION OF THE
STUDY POPULATION
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TABLE 1: SHOWING THE COMPARISION OF AGE
DISTRIBUTION OF THE STUDY POPULATION, IN PATIENTS
WTH AND WITHOUT METABOLIC SYNDROME.
AGE
GROUP
TOTAL
(n = 62)
PATIENTS
WITH
METABOLIC
SYNDROME
(n = 35)
PATIENTS
WITHOUT
METABOLIC
SYNDROME
(n = 27)
PREVALENCE
OF
METABOLIC
SYNDROME
<20
YEARS
0 0 0 0
21 – 30
YEARS
3 3 0 100%
31 – 40
YEARS
26 16 10 61%
>41
YEARS
33 16 17 48%
TOTAL 62 35 27 56%
MEAN AGE : 39.98 S.D.  :  4.73
MINUMUM AGE: 27 YEARS
MAXIMUM AGE: 45 YEARS
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GRAPH 3: SHOWING THE COMPARISION OF AGE
DISTRIBUTION IN PATIENTS WITH AND WITHOUT
METABOLIC SYNDROME
GRAPH 4: SHOWING THE PREVALENCE OF SMOKING
AMONG STUDY POPULATION.
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GRAPH5: SHOWING THE COMPARISION OF SMOKERS AND
NON SMOKERS IN PATIENTS WITH AND WITHOUT
METABOLIC SYNDROME
GRAPH 6: SHOWING THE PREVALENCE OF ALCOHOL
INTAKE AMONG THE STUDY POPULATION
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GRAPH 7: SHOWING THE COMPARISION OF INCREASED
WAIST CIRCUMFERENCE AMONG PATIENTS WITH AND
WITHOUT METABOLIC SYNDROME
GRAPH 8: SHOWING THE COMPARISION OF ELEVATED
BLOOD PRESSURE AMONG PATIENTS WITH AND WITHOUT
METABOLIC SYNDROME
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GRAPH 9: SHOWING THE COMPARISION OF ELEVATED
FASTING BLOOD SUGAR AMONG PATIENTS WITH AND
WITHOUT METABOLIC SYNDROME
GRAPH 10: SHOWING THE COMPARISION OF
HYPERTRIGLYCERIDEMIA AMONG PATIENTS WITH AND
WITHOUT METABOLIC SYNDROME
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GRAPH 11: SHOWING THE COMPARISION OF DECREASED
HDL AMONG PATIENTS WITH AND WITHOUT METABOLIC
SYNDROME
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TABLE 2: SHOWING THE CLINICAL CHARACTERISTICS OF
THE STUDY POPULATION
CHARACTERISTICS PATIENTS
WITH
METABOLIC
SYNDROME
(n = 35)
PATIENTS
WITHOUT
METABOLIC
SYNDROME
(n = 27)
P
VALUE
DEMOGRAPHIC
FACTORS
AGE
38.6±5.45 41.5±3.1
NS
MALE 32 25 NS
FEMALE 6 2 NS
POST MENOPAUSAL 3 -
SMOKER 25 22 NS
NON SMOKER 10 5 NS
ALCOHOLIC 24 22 NS
NON ALCOHOLIC 11 5 NS
VEGETARIAN DIET 3 1 NS
NON VEGETARIAN
DIET
32 26 NS
COMPONENTS
INCREASED WAIST
CIRCUMFERENCE 35 7 NS
HIGH BLOOD
PRESSURE
25 11 NS
ELEVATED
TRIGLYCERIDES
27 19 p<0.001
LOW HDL 23 15 p<0.001
ELEVATED FASTING
GLUCOSE
31 7 p<0.001
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DISCUSSION
This study is conducted on patients admitted to the Coronary Care Unit
(CCU) of Government Rajaji Hospital, Madurai during the period of
February 2016 to July 2016. All patients admitted with a diagnosis of
AMI with age less than 45 years to the Coronary Care Unit (CCU) are
included in the study. Acute myocardial infarction is defined as at least
two of the following: prolonged chest discomfort, typical
electrocardiographic changes, or elevated
Cardiac troponin levels, as outlined by the Joint European Society of
Cardiology/American College of Cardiology Committee. Patients
with Rheumatic heart disease, congenital heart disease, severe
anemia, chronic kidney and liver disease, cocaine abuse, lack of
definitive MI criteria and Age > 45 years are excluded from the
study. A total of about 62 patients were studied during the given
period after satisfying the inclusion criteria and obtaining written
consent from the patients. Patients who satisfied the international
diabetes federation criteria were diagnosed to have metabolic
syndrome.
Age distribution
A total of about sixty two patients were studied, of which 35 (56%)
of the patients fulfilled the criteria for metabolic syndrome.
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Remaining patients with age <45 years and Acute myocardial
infarction without metabolic syndrome constituted 44% (n= 27).
The mean age for patients with metabolic syndrome is 38.6 with a
standard deviation of ±5.45. The mean age for patients without
metabolic syndrome is 41.51, with a standard deviation of ±3.13
There were no patients below 20 years of age. Between 21 and 30
years, there were 3 patients all of whom were males. Between 31 and
40 years there were 26 patients, of whom 25 were males and one
female. More than 41 years, there were 33 patients, oh who 26 were
males and 7 females.(graph 2)
All the 3 patients between 21 and 30 years had metabolic syndrome.
Between 31 and 40 years (n=26), 16 patients (61/%) of them satisfied
the criteria for metabolic syndrome (graph 3).  In the age group of >
41 years (n=33), 16 patients (48%) had metabolic syndrome. The
overall prevalence of metabolic syndrome (n=62), was 56% (n=35).
From the table 1, it is obvious that younger age groups had higher
prevalence of metabolic syndrome than older age groups.
Sex distribution
Data from graph 1 reveals that out of 62 patients, 87% (n=54) of the
patients were males and 13% (n=8) females.
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Prevalence of smokers
The prevalence of smokers was 76% among the study population, as
seen in the graph 4. Among patients who satisfied the criteria for
metabolic syndrome, 71% (n=25) of the patients were smokers and
remaining 29% were non smokers. Among patients without
metabolic syndrome 66% (n=8) were smokers and remaining 34%
non-smokers. However the p value  is not significant in our study  to
say that smoking increases the prevalence of metabolic syndrome or
myocardial infarction.
Prevalence of alcoholism
In our study, the prevalence of alcoholics was 74% and non
alcoholics 26%. (graph6)
PREVALENCE OF INDIVIDUAL COMPONENTS OF
METABOLIC SYNDROME
WAIST CIRCUMFERENCE
Increased waist circumference >80 for female and> 90 for males is the
mandatory criteria to diagnose metabolic syndrome according to IDF
criteria. In our study 42 patients had increased waist circumference of
which 35 patients satisfied the remaining criteria for metabolic
syndrome. Of the 27 patients without MS, 7 patients (26%) had
increased waist circumference. (Graph 7). In a study done by N Ranjith
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et al in department of cardiology at Nelson Mandela School of medicine,
increased waist circumference was present in 16% of the young MI
patients without metabolic syndrome.
ELEVATED BLOOD PRESSURE
Elevated blood pressure >130/80 is an important criteria for diagnosing
metabolic syndrome. It is present in about 71% (n=25) of the patients
with metabolic syndrome and 40% (n=11) of patients without metabolic
syndrome (Graph8). In a study done by N Ranjith et al in Department Of
Cardiology at Nelson Mandela School of medicine, elevated blood
pressure was present in about 51% of patients with metabolic syndrome
and 29% of patients without metabolic syndrome.
FASTING BOOD SUGAR
Elevated fasting blood sugar >100mg/dl is present in about 88% of
patients with metabolic syndrome and 28% of patients without metabolic
syndrome (graph 9). In a study done by N Ranjith et al in department of
cardiology at Nelson Mandela School of medicine, elevated fasting
glucose is present n 91% of patients with metabolic syndrome and 71%
of patients without metabolic syndrome.
HYPERTRIGLYCERIDEMIA
Increased levels of fasting triglyceride is seen in about 77 % (n=27) of
patients with metabolic syndrome and 70% (n=19) of the patients
without metabolic syndrome(graph 10). In a study done by N Ranjith et
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al in department of cardiology at Nelson Mandela School of medicine,
elevated TGL was present in about 78% of patients with metabolic
syndrome and 42% of patients without metabolic syndrome.
DECREASED HDL
Decreased HDL in seen in about 66% (n=23) of patients with metabolic
syndrome and 55% (n=15) of the patients without metabolic syndrome
(graph11). In a study done by N Ranjith et al in department of cardiology
at Nelson Mandela School of medicine, decreased HDL is present in
67% of patients with metabolic syndrome and 54% of patients without
metabolic syndrome.
Our study shows a strong relationship of metabolic syndrome with
myocardial infarction in young patients <45years.Of the individual
components of metabolic syndrome, elevated fasting blood sugar has the
highest positive predictive value of 88% followed by increased
triglyceride levels in 77% , elevated blood pressure in 71% and
decreased HDL in 66% of the patients.
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CONCLUSION
Metabolic syndrome is highly prevalent in young patients with acute
myocardial infarction. Hence all measures must be undertaken to prevent
the cardiovascular events in these patients.
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SUMMARY
 The metabolic syndrome also is a collection of systemic
abnormalities that confer a person with it to high risk of
cardiovascular disease (CVD).
 Each component of metabolic syndrome is an independent risk
factor for cardiovascular and cerebrovascular disease.
 The metabolic syndrome is increasing in prevalence as result of
rapid urbanisation
 Obesity, sedentary lifestyle, smoking and insulin resistance are
important risk factors for metabolic syndrome
 Metabolic syndrome is diagnosed by various criteria like ATP III
criteria, WHO criteria and IDF criteria.
 Indians have a higher risk for CAD at comparatively lower waist
circumference than western people.
 Indians have a lower cutoff for waist circumference for diagnosing
metabolic syndrome (>80cm for females and > 90cm for males)
 Increasing prevalence of myocardial infarction in young
individuals is mainly due to increased in prevalence of metabolic
syndrome.
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PROFORMA:
Name:
Age / Sex:
IP no:
Occupation:
Presenting complaints:
Past History:
h/o previous MI/ CAD
H/o DM, HT, CKD, CVD, DRUG INTAKE, Thyroid
disorders, Personal history
cocaine abuse
smoker/ nonsmoker
alcoholic/ non alcoholic
vegetarian/ non vegetarian
Family H/o CAD
Clinical Examination:
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General Examination:
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,
hydration status
Vitals:
PR
BP
RR
SpO2
Anthropometry:
Waist circumference
Height
Weight
Systemic examination:
CVS:
RS:
ABDOMEN:
CNS:
Laboratory investigations:
Fasting lipid profile
Fasting plasma glucose
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ABBREVIATIONS
MS Metabolic Syndrome
HDL High Density Lipoprotein
LDL Low Density Lipoprotein
VLDL Very Low Density Lipoprotein
TGL Triglycerides
BP Blood Pressure
FBS Fasting Blood Sugar
CVD Cardio Vascular Disease
DM Diabetes Mellitus
94
95
96
97
